VolitionRx Ltd (VNRX) stock
VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$0.20−0.03 (-13.13%)
Close on Nov 16, 2026Market cap $2.73MP/E –Yield –
VolitionRx ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
VolitionRx's ebitda for the twelve months ending Jun 30, 2026 was -$18.55M. For fiscal 2025 it was -$20.75M. The highest annual figure on record is -$2.49M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.75M | – |
| FY2024 | Dec 31, 2024 | -$25.91M | – |
| FY2023 | Dec 31, 2023 | -$34.84M | – |
| FY2022 | Dec 31, 2022 | -$30.84M | – |
| FY2021 | Dec 31, 2021 | -$27.39M | – |
| FY2020 | Dec 31, 2020 | -$20.53M | – |
| FY2019 | Dec 31, 2019 | -$15.37M | – |
| FY2018 | Dec 31, 2018 | -$17.26M | – |
| FY2017 | Dec 31, 2017 | -$14.17M | – |
| FY2016 | Dec 31, 2016 | -$12.12M | – |
| FY2015 | Dec 31, 2015 | -$9.77M | – |
| FY2014 | Dec 31, 2014 | -$5.81M | – |
| FY2013 | Dec 31, 2013 | -$4.43M | – |
| FY2012 | Dec 31, 2012 | -$3.95M | – |
| FY2011 | Dec 31, 2011 | -$2.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.59M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.58M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.55M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.33M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.47M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.69M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.29M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.47M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.88M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.31M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.25M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.40M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.40M | – |
See a number that looks wrong?